目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T4481 | HDAC | ||
Tucidinostat (Chidamide) 是一种可口服的 HDAC I 类 HDAC1/2/3和第 IIb 类 HDAC10的抑制剂,IC50值分别为 95、160、67 和 78 nM。 | |||
T1983 | HDAC | ||
CAY10603 (BML-281) 是一种选择性 HDAC6抑制剂,IC50值为 2 pM。它也可抑制 HDAC1、HDAC2、HDAC3、HDAC8 和 HDAC10,IC50值分别为 271、252、0.42、6851和90.7 nM。 | |||
T4389 | HDAC | ||
SR-4370 是一种有效的HDAC 抑制剂,对 HDAC1、HDAC2、HDAC3、HDAC6 和 HDAC8 的IC50值分别为 0.13、0.58、0.006、3.4 和 2.3 μM。 | |||
T5830 | HDAC | ||
SKLB-23bb 是一种口服生物可利用的 HDAC6 选择性抑制剂,还具有微管破坏能力,IC50为 17 nM。它比HDAC1和HDAC8选择性分别高 25 倍和 200 倍,IC50为 422 和 3398 nM。 | |||
T6061 | HDAC | ||
LMK-235 是一种有效的 HDAC 抑制剂,可用于癌症研究。它可抑制 HDAC1、HDAC2、HDAC4、HDAC5、HDAC6、HDAC11 和 HDAC8 的活性,IC50值分别为 320 nM、881 nM、11.9 nM、4.22 nM、55.7 nM、852 nM 和 1278 nM。 | |||
T3661 | HDAC | ||
Citarinostat (ACY241) 是一种强效、选择性和口服组蛋白脱乙酰酶 (HDAC) 抑制剂,具有抗肿瘤活性,对 HDAC1、HDAC2、HDAC3、HDAC6 和 HDAC8 的 IC50分别为 35、45、46、2.6 和 137 nM。 | |||
T27081 | |||
CRA-19156 is a potent HDAC8 inhibitor. | |||
T27645 | |||
J1038 is a novel Histone Deacetylase 8 (HDAC8) Inhibitor . | |||
T16805 | HDAC | ||
RTS-V5 is a dual inhibitor of HDAC/proteasome (IC50s: 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively). | |||
T21421 | |||
NCC-149 is a HDAC8 inhibitor. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-02317 | HDAC8 Protein, Mouse, Recombinant (His) | Mouse | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|
|||||
TMPY-01333 | HDAC8 Protein, Human, Recombinant (GST) | Human | Baculovirus-Insect Cells | ||
Histone deacetylase 8, also known as HDAC8 and HDACL1, is a nucleus and cytoplasm protein that belongs to the histone deacetylase family and HD type 1 subfamily. Histone deacetylases (HDACs) are a growing family of enzymes implicated in transcriptional regulation by affecting the acetylation state of core histones in the nucleus of cells. HDAC8 / HDACL1 is weakly expressed in most tissues. It is expressed at a higher level in the heart, brain, kidney, and pancreas and also in the liver, lung, placenta, prostate, and kidney. HDAC8 / HDACL1 is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones ( H2A, H2B, H3, and H4 ). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. HDAC8 / HDACL1 may play a role in smooth muscle cell contractility. HDAC8 / HDACL1 may be a potential drug target for neuroblastoma differentiation therapy using selective inhibitors, avoiding unspecific side effects.
|